Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AICE: IP Cisplatin and Etoposide in Ovarian Cancer
NCT01669226Phase 2Completed
- Sponsor
- Shanghai Gynecologic Oncology Group
- Start
- Apr 2009
- Primary completion
- Sep 2015
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132), etoposide in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Shanghai Gynecologic Oncology Group. Started Apr 2009; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)etoposide
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01669226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01669226.